GnRH antagonist cetrorelix prevents sexual maturation of peripubertal male rats

Summary:

Gonadotropin releasing-hormone (GnRH) analogues contain amino acid substitutions of the native decapeptide. Depending on the substitutions, the analogues have GnRH agonistic or antagonistic properties. GnRH agonists are the established treatment in cases of central precocious puberty caused by premature activation of the hypothalamic GnRH pulse generator. Much less data exist on the use of GnRH antagonists to influence the onset of puberty. Using the GnRH antagonist cetrorelix we conducted a 5 day treatment of peripubertal male rats (cetrorelix group n = 12, 100 μg/d intraperitoneally injected; placebo n = 10, NaCl 0.9% intraperitoneally injected) from postnatal day 32 to 36 and decapitated on postnatal day 37 to investigate the effects on pubertal development, serum gonadotropin and testosterone levels as well as the GnRH release from explanted hypothalami. A control group of 5 male rats was added for hypothalamus superfusion experiments on day 25. We observed no progress of testicular development in the cetrorelix group. Cetrorelix injected rats had lower testicular weights (531 ± 13 versus controls 819 ± 25 mg, mean ± SEM, p < 0.0001). 12 h after the last injection testosterone levels were in the castrate range (serum testosterone, median controls: 1.7 ng/ml, median cetrorelix <0.30 ng/ml, p < 0.001), and they showed lower serum LH and FSH compared to the same age placebo group. After decapitation the preoptic mediobasal hypothalamic area (POA/MBH) was dissected from 5 randomly selected rats from each treatment group and the release rates of GnRH were determined in superfusion experiments: The hypothalamic GnRH secretion was comparable in the CET and the same age placebo rats but significantly higher than in the 25 day old control group. Conclusion: The GnRH antagonist cetrorelix inhibits the pituitary-gonadal axis in peripubertal male rats and may be effective in treating central precocious puberty in males.

GnRH-antagonist - male rats - puberty - hormone levels

References

• 1 Albano C, Felberbaum R E, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, Devroey P. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin.  Hum Reprod. 15 526-531 2000; 
• 2 Aslam H, Rosiepen G, Krishnamurthy H, Arslan M, Clemen G, Nieschlag E, Weinbauer G F. The cycle duration of the seminiferous epithelium remains unaltered during GnRH antagonist-induced testicular involution in rats and monkeys.  J Endocrinol. 161 281-288 1999; 
• 3 Behre H M, Klein B, Steinmeyer E, McGregor G P, Voight K, Nieschlag E. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men.  J Clin Endocrinol Metab. 75 393-398 1992; 
• 4 Behre H M, Kliesch S, Pühse G, Reissmann T, Nieschlag E. High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men.  J Clin Endocrinol Metab. 82 1403-1408 1997; 
• 5 Bokser L, Srkalovic G, Szepeshazi K, Schally A V. Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75).  Neuroendocrinology. 54 136-145 1991; 
• 6 Bourguignon J P, Franchimont P. Puberty-related increase in episodic LHRH release from rat hypothalamus in vitro.  Endocrinology. 114 1941-1943 1984; 
• 7 Bourguignon J P, Gerard A, Franchimont P. Maturation of the hypothalamic control of pulsatile gonadotropin-releasing hormone secretion at onset of puberty: II. Reduced potency of an inhibitory autofeedback.  Endocrinology. 127 2884-2890 1990; 
• 8 Comaru-Schally A M, Brannan W, Schally A V, Colcolough M, Monga M. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia.  J Clin Endocrinol Metab. 83 3826-3831 1998; 
• 9 Emons G, Schulz K D. Primary and salvage therapy with LH-RH analogues in ovarian cancer.  Recent Results Cancer Res. 153 83-94 2000; 
• 10 Felberbaum R, Reissmann T, Kupker W, Al-Hasani S, Bauer O, Schill T, Zoll C, Diedrich C, Diedrich K. Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages.  J Assist Reprod Genet. 13 216-222 1996; 
• 11 Feleder C, Jarry H, Leonhardt S, Moguilevsky J A, Wuttke W. Evidence to suggest that gonadotropin-releasing hormone inhibits its own secretion by affecting hypothalamic amino acid neurotransmitter release.  Neuroendocrinol. 64 298-304 1996; 
• 12 Haviv F, Bush E N, Knittle J, Greer J. LHRH antagonists.  Pharm Biotechnol. 11 131-149 1998; 
• 13 Johnson E S, Gendrich R L, White W F. Delay of puberty and inhibition of reproductive processes in the rat by a gonadotropin-releasing hormone agonist analog.  Fertil Steril. 27 853-860 1976; 
• 14 Lamharzi N, Schally A V, Koppan M. Luteinizing hormone-releasing hormone (LH-RH) antagonist cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors.  Regul Pept. 77 185-192 1998; 
• 15 Landymore K M, Wilkinson M. Chronic treatment with [D-Ala6, des Gly-NH2(10)]-LHRH ethylamide reversibly delays puberty in the female rat.  Can J Physiol Pharmacol. 62 853-855 1984; 
• 16 Lin Y, Kahn J A, Hillensjo T. Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist?.  Hum Reprod. 14 885-888 1999; 
• 17 Morale M C, Batticane N, Bartoloni G, Guarcello V, Farinella Z, Galasso M G, Marchetti B. Blockade of central and peripheral luteinizing hormone-releasing hormone (LHRH) receptors in neonatal rats with a potent LHRH-antagonist inhibits the morphofunctional development of the thymus and maturation of the cell-mediated and humeral immune responses.  Endocrinology. 128 1073-1085 1991; 
• 18 Oostdijk W, Drop S L, Odink R J, Hummerlink R, Partsch C J, Sippell W G. Long-term results with a slow-release gonadotrophin-releasing hormone agonist in central precocious puberty. Dutch-German Precocious Puberty Study Group.  Acta Paediatr Scand Suppl. 372 39-45 1991; 
• 19 Partsch C J, Peter M, Sippell W G. Leuprorelindepot zur Behandlung der progressiven Pubertas praecox vera.  Monatsschr Kinderheilkd. 147 638-647 1999; 
• 20 Partsch C J, Weinbauer G F, Schlatt S, Schiedermaier U, Schönau E, Sippell W G, Nieschlag E. Differential effects of GnRH agonist and GnRH antagonist in the suppression of puberty in cynomolgus monkeys.  Horm Res 44 ((Suppl 1)) 30 1995; 
• 21 Pescovitz O H, Barnes K M, Cutler G B. Effect of deslorelin dose in the treatment of central precocious puberty.  J Clin Endocrinol Metab. 72 60-64 1991; 
• 22 Phillips A, Hahn D W, McGuire J L, Ritchie D, Capetola R J, Bowers C, Folkers K. Evaluation of the anaphylactoid activity of a new LHRH antagonist.  Life Science. 43 883-888 1988; 
• 23 Pinski J, Lamharzi N, Halmos G, Groot K, Jungwirth A, Vadillo-Buenfil M, Kakar S S, Schally A V. Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.  Endocrinology. 137 3430-3436 1996; 
• 24 Plosker G L, Brogden R N. Leuprorelin - A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.  Drugs. 48 930-967 1994; 
• 25 Reissmann T, Felberbaum R, Diedrich K, Engel J, Comaru-Schally A M, Schally A V. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview.  Hum Reprod. 10 1974-1981 1995; 
• 26 Roth C, Leonhardt S, Theiling K, Lakomek M, Jarry H, Wuttke W. Ontogeny of the GnRH-, glutaminase- and glutamate decarboxylase-gene expression in the hypothalamus of female rats.  Dev Brain Res. 110 105-114 1998; 
• 27 Sippell W G, Partsch C J, Hümmelink R, Lorenzen F. Long-term therapy with delayed-action LHRH-agonist decapeptyl depot in girls with precocious puberty. Results of an international multicenter study.  Gynäkologe. 24 108-113 1991; 
• 28 Wildt L, Marshall G, Knobil E. Experimental induction of puberty in the infantile female rhesus monkey.  Science. 207 1373-1375 1980;